Multivariate analysis of impact of risk factors on EFS and OS
| . | . | EFS . | OS . | ||||
|---|---|---|---|---|---|---|---|
| Study . | Risk factor . | HR . | 95% CI . | P value . | HR . | 95% CI . | P value . |
| AML96 | Age | 1.33 | (1.24-1.42) | <.001 | 1.33 | (1.24-1.42) | <.001 |
| Prior MDS | 1.05 | (0.87-1.28) | .60 | 0.94 | (0.77-1.15) | .57 | |
| Therapy-related AML | 0.95 | (0.67-1.33) | .75 | 1.17 | (0.83-1.64) | .37 | |
| Adverse risk (MRC) | 1.69 | (1.41-2.04) | <.001 | 1.82 | (1.52-2.17) | <.001 | |
| Marker chromosome | 1.13 | (0.91-1.40) | .28 | 1.28 | (1.03-1.58) | .02 | |
| AML96 ≤60 y | Age | 1.18 | (1.05-1.32) | .005 | 1.24 | (1.10-1.41) | .001 |
| Prior MDS | 1.10 | (0.79-1.55) | .57 | 0.99 | (0.70-1.40) | .95 | |
| Therapy-related AML | 1.11 | (0.72-1.72) | .64 | 1.30 | (0.84-2.02) | .24 | |
| Adverse risk (MRC) | 1.89 | (1.45-2.50) | <.001 | 2.17 | (1.67-2.86) | <.001 | |
| Marker chromosome | 1.56 | (1.12-2.16) | .008 | 1.54 | (1.11-2.14) | .01 | |
| AML96 >60 y | Age | 1.19 | (0.93-1.52) | .17 | 1.43 | (1.13-1.82) | .003 |
| Prior MDS | 1.04 | (0.82-1.33) | .73 | 0.94 | (0.74-1.21) | .65 | |
| Therapy-related AML | 0.85 | (0.49-1.46) | .55 | 1.07 | (0.62-1.85) | .81 | |
| Adverse risk (MRC) | 1.56 | (1.23-2.00) | <.001 | 1.59 | (1.23-2.04) | <.001 | |
| Marker chromosome | 0.93 | (0.70-1.23) | .61 | 1.19 | (0.89-1.57) | .24 | |
| AML2003 | Age | 1.08 | (0.96-1.20) | .21 | 1.18 | (1.04-1.34) | .01 |
| Prior MDS | 1.02 | (0.73-1.43) | .92 | 0.89 | (0.61-1.29) | .53 | |
| Therapy-related AML | 1.41 | (0.97-2.05) | .08 | 1.94 | (1.31-2.88) | .001 | |
| Adverse risk (MRC) | 1.67 | (1.30-2.13) | <.001 | 1.82 | (1.39-2.38) | <.001 | |
| Marker chromosome | 1.36 | (0.95-1.97) | .10 | 1.16 | (0.79-1.72) | .45 | |
| . | . | EFS . | OS . | ||||
|---|---|---|---|---|---|---|---|
| Study . | Risk factor . | HR . | 95% CI . | P value . | HR . | 95% CI . | P value . |
| AML96 | Age | 1.33 | (1.24-1.42) | <.001 | 1.33 | (1.24-1.42) | <.001 |
| Prior MDS | 1.05 | (0.87-1.28) | .60 | 0.94 | (0.77-1.15) | .57 | |
| Therapy-related AML | 0.95 | (0.67-1.33) | .75 | 1.17 | (0.83-1.64) | .37 | |
| Adverse risk (MRC) | 1.69 | (1.41-2.04) | <.001 | 1.82 | (1.52-2.17) | <.001 | |
| Marker chromosome | 1.13 | (0.91-1.40) | .28 | 1.28 | (1.03-1.58) | .02 | |
| AML96 ≤60 y | Age | 1.18 | (1.05-1.32) | .005 | 1.24 | (1.10-1.41) | .001 |
| Prior MDS | 1.10 | (0.79-1.55) | .57 | 0.99 | (0.70-1.40) | .95 | |
| Therapy-related AML | 1.11 | (0.72-1.72) | .64 | 1.30 | (0.84-2.02) | .24 | |
| Adverse risk (MRC) | 1.89 | (1.45-2.50) | <.001 | 2.17 | (1.67-2.86) | <.001 | |
| Marker chromosome | 1.56 | (1.12-2.16) | .008 | 1.54 | (1.11-2.14) | .01 | |
| AML96 >60 y | Age | 1.19 | (0.93-1.52) | .17 | 1.43 | (1.13-1.82) | .003 |
| Prior MDS | 1.04 | (0.82-1.33) | .73 | 0.94 | (0.74-1.21) | .65 | |
| Therapy-related AML | 0.85 | (0.49-1.46) | .55 | 1.07 | (0.62-1.85) | .81 | |
| Adverse risk (MRC) | 1.56 | (1.23-2.00) | <.001 | 1.59 | (1.23-2.04) | <.001 | |
| Marker chromosome | 0.93 | (0.70-1.23) | .61 | 1.19 | (0.89-1.57) | .24 | |
| AML2003 | Age | 1.08 | (0.96-1.20) | .21 | 1.18 | (1.04-1.34) | .01 |
| Prior MDS | 1.02 | (0.73-1.43) | .92 | 0.89 | (0.61-1.29) | .53 | |
| Therapy-related AML | 1.41 | (0.97-2.05) | .08 | 1.94 | (1.31-2.88) | .001 | |
| Adverse risk (MRC) | 1.67 | (1.30-2.13) | <.001 | 1.82 | (1.39-2.38) | <.001 | |
| Marker chromosome | 1.36 | (0.95-1.97) | .10 | 1.16 | (0.79-1.72) | .45 | |
Statistically significant effects are set in bold. P values of the Wald tests for the model coefficients HRs and 95% CIs are given for the respective clinical trials. The Cox models for all patients were stratified by study.
CI, confidence interval; HR, hazard ratio; t-AML, therapy-related acute myeloid leukemia.